Carvedilol
- PDF / 577,493 Bytes
- 45 Pages / 504.57 x 720 pts Page_size
- 32 Downloads / 134 Views
Drugs 2003; 63 (16): 1697-1741 0012-6667/03/0016-1697/$33.00/0 © Adis Data Information BV 2003. All rights reserved.
Carvedilol A Review of its Use in Chronic Heart Failure Gillian M. Keating and Blair Jarvis Adis International Limited, Auckland, New Zealand Various sections of the manuscript reviewed by: A. Di Lenarda, Department of Cardiology, Ospedale Maggiore, Trieste, Italy; R.N. Doughty, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; M. Flesch, Winters Heart Failure Center, VA Medical Center, Houston, Texas, USA; A. Ignaszewski, Cardiac Transplant Program, St. Paul’s Hospital, Vancouver, British Columbia, Canada; H. Krum, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; A. Lahiri, Department of Cardiovascular Medicine, Northwick Park Hospital and Institute for Medical Research, Harrow, UK; J.E. Sanderson, Division of Cardiology, Prince of Wales Hospital, Shatin, Hong Kong; K. Teo, Division of Cardiology, McMaster University, Hamilton, Ontario, Canada.
Data Selection Sources: Medical literature published in any language since 1997 on carvedilol, identified using AdisBase (a proprietary database of Adis International), Medline and EMBASE. Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Search strategy: AdisBase search terms were ‘carvedilol’ or ‘BM-14190’ or ‘DQ-2466’ and ‘congestive-heart-failure’. Medline search terms were ‘carvedilol’ and ‘heart-failure-congestive’. EMBASE search terms were ‘carvedilol’ and ‘congestive-heart-failure’. Searches were last updated 5 July 2003. Selection: Studies in patients with chronic heart failure who received carvedilol. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included. Index terms: Carvedilol, heart failure, pharmacodynamics, pharmacokinetics, therapeutic use.
Contents Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1698 1. Pharmacodynamic Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1705 1.1 Receptor Affinity and Effects on Adrenergic Activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1705 1.2 Haemodynamic Effects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1707 1.2.1 During Exercise . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1710 1.2.2 In Diastolic Dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Data Loading...
